Duffy Sean P. sold $327K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 14,960 shares of Omada Health, Inc. (OMDA) at an average of $21.87 ($21.80–$22.59, $0.33M total) across 2 trades on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Sep 14, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 9:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect OMDA's share price, but it provides transparency for shareholders.

02

Market read

A routine insider sell with limited market impact; useful for compliance monitoring.

03

What to watch

Potential upcoming corporate actions or earnings that prompted the pre‑arranged sale.

Relevance 3/10Novelty 3/10Timing: sale reported Sep 14, covering a Sep 10 transaction

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

CEO Sean Duffy sold 14,960 shares for $327K via a 10b5‑1 plan on Sep 10, 2026.

Expected impact

No significant price impact expected.

Evidence & confidence

The transaction size is small relative to market cap and follows a pre‑arranged plan, so it carries limited informational value.

Market effects

None; the sale is company‑specific and does not affect the digital health sector.

None; the filing is U.S.‑focused and does not influence broader regional markets.

Minimal; only relevant to investors tracking OMDA.

Counterpoint

The sell could be interpreted as a lack of confidence, but the 10b5‑1 plan suggests it is routine.

Key entities

  • Omada Health, Inc.

    Digital health platform listed on Nasdaq under ticker OMDA.

  • Sean P. Duffy

    Chief Executive Officer of Omada Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.